Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Newsletter Article
|
Corcept: Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients with HypercortisolismManufacturing Close - Up, 2024Copyright Close-Up Media, Inc. Jun 4, 2024Digital Resources/Online E-Resources |
|
2 |
Material Type: Newsletter Article
|
Corcept Therapeutics (CORT: $32.87) up 8.9% in 2 days, hits 263-day high; +$2.70 [8.9%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 4, 2024Digital Resources/Online E-Resources |
|
3 |
Material Type: Newsletter Article
|
Corcept Therapeutics (CORT: $31.30) up 3.7% after an upgrade this week; +$1.13 [3.7%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 3, 2024Digital Resources/Online E-Resources |
|
4 |
Material Type: Newsletter Article
|
Weekly: Corcept Therapeutics (CORT: $30.13) in top 1% performers of NASDAQ market in past week; +$2.61 [9.5%] Vol Index 1.7 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 3, 2024Digital Resources/Online E-Resources |
|
5 |
Material Type: Newsletter Article
|
Monthly: Corcept Therapeutics (CORT: $30.17) adds $727 million in MCap in May, leads Medical/Drugs sector gainsNews Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 3, 2024Digital Resources/Online E-Resources |
|
6 |
Material Type: Newsletter Article
|
Monthly: Achieve Life Sciences (ACHV: $5.22) rises 19% on high volatility in May 2024News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 3, 2024Digital Resources/Online E-Resources |
|
7 |
Material Type: Newsletter Article
|
Press Release: KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerDow Jones Institutional News, 2024Copyright Dow Jones & Company Inc. Jun 1, 2024Digital Resources/Online E-Resources |
|
8 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $5.22) accelerates decline, down 2.2% in 2 days; -12c [2.2%] Vol Index 1.8 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 1, 2024Digital Resources/Online E-Resources |
|
9 |
Material Type: Newsletter Article
|
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerBusiness Wire, 2024Copyright Business Wire 2024Digital Resources/Online E-Resources |
|
10 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $5.29) decreases, 2 days' volume in a day; -5c [0.9%] Vol Index 1.7 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 31, 2024Digital Resources/Online E-Resources |
|
11 |
Material Type: Newsletter Article
|
Corcept Therapeutics (CORT: $30.13) offers earnings yield of 3.3News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 31, 2024Digital Resources/Online E-Resources |
|
12 |
Material Type: Newsletter Article
|
Corcept Therapeutics top gainer in Roanoke Asset Management jumps 23.9% in 63 days; -$1.08 [3.5%] Vol Index 1.2 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 31, 2024Digital Resources/Online E-Resources |
|
13 |
Material Type: Newsletter Article
|
Corcept Therapeutics (CORT: $31.21) loses $33 million (1.0%) in MCap, steepest heavyweight fall in Medical/Drugs sector; -32c [1.0%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 30, 2024Digital Resources/Online E-Resources |
|
14 |
Material Type: Newsletter Article
|
Clinical Trial: Prevalence of Birth Before Arrival and Associated Factors Among Postpartum Women in Southern EthiopiaUS Fed News Service, Including US State News, 2024Copyright HT Digital Streams Limited May 30, 2024Digital Resources/Online E-Resources |
|
15 |
Material Type: Newsletter Article
|
Achieve Life Sciences top gainer in Propel Bio Management jumps 17.9% in 61 days, hits 173-day high; -3c [0.6%] Vol Index 1.6 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 30, 2024Digital Resources/Online E-Resources |
|
16 |
Material Type: Newsletter Article
|
Corcept Therapeutics Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushings Syndrome)News Bites - Healthcare & Equipment, 2024Copyright News Bites Pty Ltd May 29, 2024Digital Resources/Online E-Resources |
|
17 |
Material Type: Newsletter Article
|
Achieve Life Sciences (ACHV: $5.36) falls 3.9% from 14-day high; -5c [0.9%] Vol Index 2.0 [1 is avg]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 29, 2024Digital Resources/Online E-Resources |
|
18 |
Material Type: Newsletter Article
|
Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Phase 3 StudyPR Newswire, 2024Copyright PR Newswire Association LLC May 29, 2024Digital Resources/Online E-Resources |
|
19 |
Material Type: Newsletter Article
|
Press Release: Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Phase 3 StudyDow Jones Institutional News, 2024Copyright Dow Jones & Company Inc. May 29, 2024Digital Resources/Online E-Resources |
|
20 |
Material Type: Newsletter Article
|
Corcept Therapeutics (CORT: $31.53) down 0.3% after a second upgrade; -8c [0.3%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 29, 2024Digital Resources/Online E-Resources |